Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kingsoft Cloud Holdings Limited (KC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Kingsoft Cloud Holdings LimitedTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Kingsoft Cloud Holdings Limited vs Zimmer Biomet Holdings Inc — how do they compare? Kingsoft Cloud Holdings Limited trades at $9.26 (market cap $2.71B), while Zimmer Biomet Holdings Inc trades at $89.19 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 6.3× Kingsoft Cloud Holdings Limited's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kingsoft Cloud Holdings Limited for 12 Days and Zimmer Biomet Holdings Inc for 89 Days on average.

KCZBH
Market Cap
$2.71B$16.95B
Volume
1,993,7652,505,240
Sector
TechnologyHealth
52-Week High
$18.21$103.98
52-Week Low
$8.58$79.58
Typical Hold Time
12 Days89 Days
Enterprise Value
$3.03B$24.02B
Dividend Yield
—1.08%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kingsoft Cloud Holdings Limited

Kingsoft Cloud (KC) trades at $9.26, up 0.27% with bearish technical signals but strong analyst support. The company shows improving fundamentals with Q2 2026 revenue growth of 30.8% year-over-year and three consecutive earnings beats. While still reporting net losses, gross margins improved significantly and AI cloud services are emerging as a key growth driver, with billings surging 82% year-over-year.

KC presents a compelling turnaround story with 70% analyst buy ratings and 60% upside potential, though risks include persistent losses, competitive pressures, and technical weakness. The AI cloud partnership with Xiaomi positions the stock for growth, but investors should weigh the fundamental improvements against the current bearish technical setup.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.

The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KC
0% Buy100% Sell
Avg holding period · 12 Days
ZBH

No sentiment data available yet.

Top news

Latest headlines on both assets

About Kingsoft Cloud Holdings Limited

Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.

Read more on KC →

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH →